| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
4008200310 |
| Email: |
marketing@tsbiochem.com |
| Products Intro: |
Product Name:Tulopafant
CAS:116289-53-3
Purity:99.38% Package:1mg/RMB 4900;5mg/RMB 12600
|
Tulopafant manufacturers
- Tulopafant
-
- $700.00 / 1mg
-
2024-11-20
- CAS:116289-53-3
- Min. Order:
- Purity: 99.38%
- Supply Ability: 10g
|
| | Tulopafant Basic information |
| Product Name: | Tulopafant | | Synonyms: | Tulopafant;1H,3H-Pyrrolo[1,2-c]thiazole-7-carboxamide, N-(3-benzoylphenyl)-3-(3-pyridinyl)-, (+)- | | CAS: | 116289-53-3 | | MF: | C25H19N3O2S | | MW: | 425.51 | | EINECS: | | | Product Categories: | | | Mol File: | 116289-53-3.mol |  |
| | Tulopafant Chemical Properties |
| Boiling point | 613.3±55.0 °C(Predicted) | | density | 1.32±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | pka | 13.51±0.70(Predicted) |
| | Tulopafant Usage And Synthesis |
| Uses | Tulopafant is a platelet activating factor (PAF) antagonist. | | in vivo | Tulopafant (RP 59227) effectively reduces myocardial infarct size and reduces the incidence of ischemia and reperfusion-induced arrhythmias in barbital-anesthetized dogs[1].Histological examination reveals marked diminution of both interstitial hemorrhage and deposition of platelet and granulocytes in capillaries of cardiac xenografts when recipient animals are pretreated with Tulopafant[2]. | | References | [1] Auchampach JA, et al. Effect of the platelet-activating factor antagonist RP 59227 (Tulopafant) on myocardial ischemia/reperfusion injury and neutrophil function. Basic Res Cardiol. 1998 Oct;93(5):361-71. DOI:10.1007/s003950050104
[2] O'Hair DP, et al. Tulopafant, a PAF receptor antagonist, increases capillary patency and prolongs survival in discordant cardiac xenotransplants. J Lipid Mediat. 1993 May;7(1):79-84. PMID:8395256 |
| | Tulopafant Preparation Products And Raw materials |
|